To Treat or Not to Treat: Patient and Physician Sharing Session #3

Source: Addressing Misunderstandings in Applying HBV Treatment Guidelines
In episode 3 of this ongoing series, listen to a conversation between Jordan J. Feld, MD, MPH, and Wendy, who is living with chronic hepatitis B, on incorporating shared decision-making to determine when to initiate treatment.
Jordan J. Feld, MD, MPH
Released: May 11, 2021

In episode 3 of an ongoing series of sharing sessions between a physician and patient, Jordan J. Feld, MD, MPH, and Wendy, who is living with chronic hepatitis B, discuss the challenges of determining the best time to start treatment. The conversation focuses on incorporating shared decision-making, particularly for cases that are not straight forward and do not fit into an one specific category outlined by the guidelines.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from:
Gilead Sciences, Inc.

Information on this Educational Activity

Faculty

Jordan J. Feld, MD, MPH

Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada

Jordan J. Feld, MD, MPH, has disclosed that he has received consulting fees from AbbVie, ContraVir, Gilead Sciences, Janssen, and Merck and funds for research support from Abbott, AbbVie, Gilead Sciences, Janssen, and Merck.

Program Medium

This program has been made available online.

Related Content

Brief Clinical Care Options (CCO) presentation on APASL guidance on limitations of current HCC surveillance recommendations in chronic HBV infection

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 7, 2021 Expired: October 6, 2022

Takeshi Saito, MD, PhD, discusses the limitations of current approaches to treating HDV and looks ahead to new and emerging HDV therapies, from Clinical Care Options (CCO)

Takeshi Saito, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 28, 2021 Expired: September 27, 2022

Download key slides describing lessons learned in delivery of care from the COVID-19 pandemic worth carrying forward in the management of viral hepatitis.

Gregory Dore, MBBS, PhD, FRACP, MPH Stacey Trooskin, MD, PhD, MPH Released: September 23, 2021

Brief Clinical Care Options (CCO) presentation on using the EASL guidelines to determine treatment candidacy in patients with hepatitis B virus HBV.

Maria Buti, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 7, 2021 Expired: September 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue